N³-benzoyl-2'-deoxy-3'-O-benzyl-5-fluorouridine | 95969-81-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: N³-benzoyl-2'-deoxy-3'-O-benzyl-5-fluorouridine
• 英文别名: 3'-O-benzyl-2'-deoxy-3-benzoyl-5-fluorouridine；3-benzoyl-5-fluoro-1-[(2R,4S,5R)-5-(hydroxymethyl)-4-phenylmethoxyoxolan-2-yl]pyrimidine-2,4-dione
• CAS: 95969-81-6
• 化学式: C₂₃H₂₁FN₂O₆
• 分子量: 440.428
• InChiKey: SIQNQEDYWLQOQS-XUVXKRRUSA-N

物化性质

• 沸点：
  582.9±60.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N³-benzoyl-2'-deoxy-3'-O-benzyl-5-fluorouridine 在 ammonium hydroxide 作用下， 以 乙醇 、 丙酮 为溶剂， 以65%的产率得到3'-O-benzyl-2'-deoxy-5-fluorouridine
  参考文献：
  名称：

  抗肿瘤药的研究。8.2′-脱氧-5-（三氟甲基）尿苷和2′-脱氧-5-氟尿苷的O-烷基衍生物的抗肿瘤活性。

  摘要：

  合成了2'-脱氧-5-（三氟甲基）尿苷（F3Thd）和2'-脱氧-5-氟尿苷（FUdR）的O-苄基和O-乙基衍生物。检查了化合物对小鼠肉瘤180的口服抗肿瘤活性。F3Thd的5'-O-乙基（3b），3'-O-乙基（3c），5'-O-苄基（3e）和3'-O-苄基（3f）衍生物的活性高4倍比F3Thd本身。在F3Thd的取代苄基衍生物中，3'-O-（对氯苄基）-F3Thd（3h）显示最高的活性，ED50不到F3Thd的十分之一。FUdR的5'-O-苄基（7c）和3'-O-苄基（7d）衍生物的活性与F3Thd的有效O-烷基衍生物的活性相等。

  DOI：

  10.1021/jm00121a025
• 作为产物：
  描述：

  5-氟-2'-脱氧脲核苷 在 三乙胺 、 silver(l) oxide 作用下， 以 N,N-二甲基乙酰胺 、 丁酮 为溶剂， 反应 12.0h， 生成 N³-benzoyl-2'-deoxy-3'-O-benzyl-5-fluorouridine
  参考文献：
  名称：

  抗肿瘤药的研究。8.2′-脱氧-5-（三氟甲基）尿苷和2′-脱氧-5-氟尿苷的O-烷基衍生物的抗肿瘤活性。

  摘要：

  合成了2'-脱氧-5-（三氟甲基）尿苷（F3Thd）和2'-脱氧-5-氟尿苷（FUdR）的O-苄基和O-乙基衍生物。检查了化合物对小鼠肉瘤180的口服抗肿瘤活性。F3Thd的5'-O-乙基（3b），3'-O-乙基（3c），5'-O-苄基（3e）和3'-O-苄基（3f）衍生物的活性高4倍比F3Thd本身。在F3Thd的取代苄基衍生物中，3'-O-（对氯苄基）-F3Thd（3h）显示最高的活性，ED50不到F3Thd的十分之一。FUdR的5'-O-苄基（7c）和3'-O-苄基（7d）衍生物的活性与F3Thd的有效O-烷基衍生物的活性相等。

  DOI：

  10.1021/jm00121a025

文献信息

• 5-fluorouracil derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04864021A1

  公开（公告）日：1989-09-05

  An anticancer compound is disclosed which is represented by the formula ##STR1## wherein one of R.sup.1 and R.sup.2 is a phenyl-lower alkyl optionally having a substituent, phenyl-lower alkenyl or naphthyl-lower alkyl, the other of R.sup.1 and R.sup.2 is hydrogen or acyl, and R.sup.3 is hydrogen, acyl or tetrahydrofuranyl, or represented by the formula ##STR2## wherein R.sup.x is an optionally substituted pyridyl, Y is arylene and .alpha. is a known 5-fluorouracil derivative residue which can be converted to 5-fluorouracil in vivo and which is linked to the carbonyl by an ester or amide linkage.

  一种抗癌化合物被披露，其由公式##STR1##表示，其中R.sup.1和R.sup.2之一是任选带有取代基的苯基-低级烷基、苯基-低级烯基或萘基-低级烷基，R.sup.1和R.sup.2的另一个是氢或酰基，R.sup.3是氢、酰基或四氢呋喃基；或者由公式##STR2##表示，其中R.sup.x是任选带有取代基的吡啶基，Y是芳香族亚烷基，.alpha.是已知的5-氟尿嘧啶衍生物残基，其可以在体内转化为5-氟尿嘧啶，并且通过酯或酰胺键与羰基相连。
• Composition for increasing the anti-cancer activity of an anti-cancer
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05155113A1

  公开（公告）日：1992-10-13

  A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula ##STR1## wherein R.sup.1 is hydroxy or acyloxy, R.sup.2 and R.sup.4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R.sup.3 and R.sup.5 are each hydrogen, hydroxy or acyloxy; when at least one or R.sup.1, R.sup.3 and R.sup.5 is hydroxy, the structure of 1-position on the pyridine ring can be ##STR2## due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, ##STR3## wherein .alpha. is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.

  一种用于增强抗癌化合物的抗癌活性的组合物，所述抗癌化合物从5-氟尿嘧啶和能够在体内产生5-氟尿嘧啶的化合物中选择，所述组合物包括有效量的由公式表示的吡啶衍生物：##STR1## 其中R.sup.1是羟基或酰氧基，R.sup.2和R.sup.4分别是氢、卤素、氨基、羧基、氨基甲酰、氰基、硝基、低碳基、低烯基或低烷氧羰基，R.sup.3和R.sup.5分别是氢、羟基或酰氧基；当R.sup.1、R.sup.3和R.sup.5中至少有一个是羟基时，吡啶环上1位的结构可以由于酮-烯醇互变异构而是##STR2## 所述氢原子连接到氮上可以选择地被下列取自所述群的取代基所取代：低碳基、四氢呋喃基、四氢吡喃基、低烷氧基-低碳基、邻苯二甲酰基、氨基甲酰-低碳基氧羰基-低烷氧基-低碳基、苯基-低烷氧基-低碳基、苯基甲酰基，所述苯环上可能有取代基，低碳基甲酰基、羧基-低碳基甲酰基、低硫基-低烷基和低烯基；但是，具有以下公式的化合物被排除：##STR3## 其中α是氢、低碳基、四氢呋喃基、四氢吡喃基、低烷氧基甲酰基、低碳基甲酰基、低硫基-低烷基或低烯基。
• Novel 2'-deoxy-5-substituted uridine derivatives, processes for preparing the same and antitumor agent containing the same
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP0129984A1

  公开（公告）日：1985-01-02

  Novel 2'-deoxy-5-substituted uridine derivative represented by the general formula, wherein R, is a hydrogen atom, a benzoyl group or a tetrahydrofuranyl group; R2 is a fluorine atom or a trifluoromethyl group; and any one of R3 and R4 is a hydrogen atom and the other one is an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a benzyl group having as the substituents selected from the group consisting of a halogen atom, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms and a nitro group, or an alkyl group having 1 to 3 carbon atoms having one or two phenyl groups as the substituents. The novel 2'-deoxy-5-substituteduridine derivative possesses excellent antitumor activity with less toxicity, thus it is useful as antitumor agent.

  由通式代表的新型 2'-脱氧-5-取代尿苷衍生物、 其中 R 是氢原子、苯甲酰基或四氢呋喃基；R2 是氟原子或三氟甲基；R3和R4中的任何一个是氢原子，另一个是具有1至10个碳原子的烷基、具有2至6个碳原子的烯基、取代基选自以下组别的苄基：卤素原子、具有1至4个碳原子的烷基、具有1至4个碳原子的烷氧基和硝基，或具有1至3个碳原子的烷基，取代基为一个或两个苯基。 新型 2'-deoxy-5 取代尿苷衍生物具有极佳的抗肿瘤活性，毒性较低，因此可用作抗肿瘤药物。
• A composition for increasing the anti-cancer activity of an anti-cancer compound
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0180188A2

  公开（公告）日：1986-05-07

  A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula wherein R1 is hydroxy or acyloxy, R2 and R4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R3 and R are each hydrogen, hydroxy or acyloxy; when at least one of R1, R3 and R5 is hydroxy, the structure of 1-position on the pyridine rina can be duetothe due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, wherein a is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.

  一种提高选自5-氟尿嘧啶和一种能在体内产生5-氟尿嘧啶的化合物的抗癌活性的组合物，该组合物包括有效量的由式表示的吡啶衍生物 其中 R1 是羟基或酰氧基，R2 和 R4 分别是氢、卤素、氨基、羧基、氨基甲酰基、氰基、硝基、低级烷基、低级烯基或低级烷氧基羰基，R3 和 R 分别是氢、羟基或酰氧基；当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是 当 R1、R3 和 R5 中至少有一个是羟基时，吡啶里纳上 1 位的结构可以是酮烯醇同分异构，所述连接到氮上的氢可选择被选自低烷基、四氢呋喃基、四氢吡喃基、低烷氧基低烷基、邻苯二甲酰基、氨基甲酰基、低烷氧基羰基低烷基氨基甲酰基组成的取代基取代、苯基-低级烷氧基-低级烷基、苯基氨基甲酰基（苯基环上可能有取代基）、低级烷基氨基甲酰基、羧基-低级烷基氨基甲酰基、低级烷硫基-低级烷基和低级烯基，但具有下式的化合物除外、 其中 a 为氢、低级烷基、四氢呋喃基、四氢呋喃基、低级烷氧基低级烷基、低级烷基氨基甲酰基、低级烷硫基低级烷基或低级烯基。
• 5-Fluorouracil derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0180897A2

  公开（公告）日：1986-05-14

  An anticancer compound is disclosed which is represented by the formula wherein one of R1 and R2 is a phenyl-lower alkyl optionally having a substituent, phenyl-lower alkenyl or naphthyl-lower alkyl, the other of R1 and R2 is hydrogen or acyl, and R3 is hydrogen, acyl or tetrahydrofuranyl, or represented by the formula wherein Rx is an optionally substituted pyridyl, Y is arylene and a is a known 5-fluorouracil derivative residue which can be converted to 5-fluorouracil in vivo and which is linked to the carbonyl by an ester or amide linkage.

  公开了一种抗癌化合物，该化合物由式表示，其中 R1 和 R2 中的一个是可选具有取代基的苯基-低级烷基、苯基-低级烯基或萘基-低级烷基，R1 和 R2 中的另一个是氢或酰基，R3 是氢、酰基或四氢呋喃基，或由式表示，其中 Rx 是可选取代的吡啶基，Y 是芳基，a 是已知的 5-氟尿嘧啶衍生物残基，该残基可在体内转化为 5-氟尿嘧啶，并通过酯或酰胺连接与羰基相连。